The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.

ABSTRACT:

Background

At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaquiline and delamanid was a critical development in the MDR-TB treatment landscape. However, despite their availability for routine programmatic use, the uptake of these drugs has remained slow; concerns included a lack of evidence on safety and efficacy and the need to protect the new drugs from the development of acquired resistance. As part of the endTB Project, we aimed to address these barriers by generating evidence on safety and efficacy of bedaquiline or delamanid based MDR-TB regimens.

Methods

This is a protocol for a multi-center prospective cohort study to enroll 2600 patients from April

SUBMITTER: Khan U 

PROVIDER: S-EPMC6701145 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature